Noxopharm Limited (ASX:NOX)
Australia · Delayed Price · Currency is AUD 0.0770
0.00 (0.00%)
Jan 30, 2026, 3:58 PM AEST
Noxopharm Revenue
In the fiscal year ending June 30, 2025, Noxopharm had annual revenue of 2.82M AUD with 17.52% growth. Noxopharm had revenue of 1.66M in the half year ending June 30, 2025, a decrease of -37.52%.
Revenue
2.82M
Revenue Growth
+17.52%
P/S Ratio
7.98
Revenue / Employee
n/a
Employees
n/a
Market Cap
22.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 2.82M | 420.56K | 17.52% |
| Jun 30, 2024 | 2.40M | -3.61M | -60.06% |
| Jun 30, 2023 | 6.01M | 581.44K | 10.71% |
| Jun 30, 2022 | 5.43M | -179.61K | -3.20% |
| Jun 30, 2021 | 5.61M | -2.67M | -32.29% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 12.68M |
| Immuron | 7.29M |
| Argenica Therapeutics | 3.21M |
| Tissue Repair | 2.63M |
| Neurotech International | 2.44M |
| Entropy Neurodynamics | 1.58M |
| Avecho Biotechnology | 1.38M |
| Patrys | 828.54K |